EA200400605A1 - Способы и средства получения белков с заранее заданными посттрансляционными модификациями - Google Patents

Способы и средства получения белков с заранее заданными посттрансляционными модификациями

Info

Publication number
EA200400605A1
EA200400605A1 EA200400605A EA200400605A EA200400605A1 EA 200400605 A1 EA200400605 A1 EA 200400605A1 EA 200400605 A EA200400605 A EA 200400605A EA 200400605 A EA200400605 A EA 200400605A EA 200400605 A1 EA200400605 A1 EA 200400605A1
Authority
EA
Eurasian Patent Office
Prior art keywords
post
mammalian cells
translational modifications
obtaining
present
Prior art date
Application number
EA200400605A
Other languages
English (en)
Other versions
EA008220B1 (ru
Inventor
Дирк Ян Элбертус Опстелтен
Йохан Кристиан Каптейн
Петрус Кристианус Йоханнес Йосефус Пассир
Роланд Хендрик Петер Брюс
Абрахам Баут
Original Assignee
Круселл Холланд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2001/000792 external-priority patent/WO2003050286A1/en
Priority claimed from PCT/NL2002/000257 external-priority patent/WO2003089468A1/en
Application filed by Круселл Холланд Б.В. filed Critical Круселл Холланд Б.В.
Publication of EA200400605A1 publication Critical patent/EA200400605A1/ru
Publication of EA008220B1 publication Critical patent/EA008220B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

Настоящее изобретение относится к способам идентификации, отбора и получения клеток млекопитающих, которые способны продуцировать белковые молекулы с заранее заданными посттрансляционными модификациями, где указанные посттрансляционные модификации осуществляются в клетке млекопитающего, в которой белковая молекула экспрессируется. Предпочтительно указанные заранее заданные посттрансляционные модификации включают гликозилирование. Изобретение относится также к способам получения и продуцирования белковых молекул с использованием клеток млекопитающих, получаемых по способу настоящего изобретения. Предпочтительно указанные белковые молекулы включают эритропоэтин (ЭП), поскольку эффект (рекомбинантного) ЭП зависит в значительной мере от характера гликозилирования олигосахаридов, имеющихся в белке. Клетки млекопитающих, которые были получены на основе их способности продуцировать белки и/или посттрансляционные модификации, которые являются показательными для заранее заданной посттрансляционной модификации и которые являются желательными, также обеспечиваются настоящим изобретением. Предпочтительно указанные клетки млекопитающих имеют характеристики и свойства нервных клеток, так что могут быть получены значительные количества рекомбинантных белков, которые обладают свойствами «невронального или мозгового типа».Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200400605A 2001-10-29 2002-10-29 Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения EA008220B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NL2001/000792 WO2003050286A1 (en) 2001-10-29 2001-10-29 Methods and means for producing proteins with predetermined post-translational modifications
PCT/NL2002/000257 WO2003089468A1 (en) 2002-04-19 2002-04-19 Methods and means for producing proteins with predetermined post-translational modifications
PCT/NL2002/000686 WO2003038100A1 (en) 2001-10-29 2002-10-29 Methods and means for producing proteins with predetermined post-translational modifications

Publications (2)

Publication Number Publication Date
EA200400605A1 true EA200400605A1 (ru) 2004-08-26
EA008220B1 EA008220B1 (ru) 2007-04-27

Family

ID=26642018

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200602163A EA012340B1 (ru) 2001-10-29 2002-10-29 Способ получения гликозилированной белковой молекулы, содержащей структуру lewis x, и/или сиалил-lewis x, и/или lacdinac
EA200400605A EA008220B1 (ru) 2001-10-29 2002-10-29 Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200602163A EA012340B1 (ru) 2001-10-29 2002-10-29 Способ получения гликозилированной белковой молекулы, содержащей структуру lewis x, и/или сиалил-lewis x, и/или lacdinac

Country Status (14)

Country Link
US (3) US7304031B2 (ru)
EP (2) EP2292770B1 (ru)
JP (1) JP4583029B2 (ru)
CN (1) CN100347306C (ru)
AT (1) ATE542904T1 (ru)
AU (1) AU2002335585B2 (ru)
BR (1) BR0213402A (ru)
CA (2) CA2465007C (ru)
DK (1) DK1440157T3 (ru)
EA (2) EA012340B1 (ru)
ES (1) ES2381104T3 (ru)
IL (3) IL161674A (ru)
NO (1) NO20042209L (ru)
WO (1) WO2003038100A1 (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
WO2003048348A2 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AU2002335585B2 (en) * 2001-10-29 2007-08-16 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
CA2560185C (en) * 2004-03-17 2013-05-07 Crucell Holland B.V. Novel assay for the separation and quantification of hemagglutinin antigens
EP1844068A4 (en) * 2005-01-25 2009-09-30 Apollo Life Sciences Ltd MOLECULES AND THEIR CHIMERIC MOLECULES
CN101247822B (zh) * 2005-06-01 2012-10-17 新潟Tlo株式会社 含有epo衍生物的血液相关疾病的治疗剂
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
AU2006316838B2 (en) * 2005-11-15 2012-04-12 Glycofi, Inc Production of glycoproteins with reduced O-glycosylation
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
WO2007098548A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
EP2047859A4 (en) 2006-06-07 2010-05-05 Univ Tokushima TREATMENT OF ISCHEMIC DISEASE USING ERYTHROPOIETIN
WO2008023725A1 (fr) 2006-08-22 2008-02-28 Chugai Seiyaku Kabushiki Kaisha Agent préventif et/ou thérapeutique pour une neuropathie périphérique
AR065613A1 (es) 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
AU2008243007A1 (en) 2007-04-16 2008-10-30 Momenta Pharmaceuticals, Inc. Characterization of N-glycans using exoglycosidases
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
US8138092B2 (en) 2009-01-09 2012-03-20 Lam Research Corporation Spacer formation for array double patterning
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CN103619358B (zh) 2011-03-31 2017-02-15 辉凌公司 药物制剂
EP2773964A4 (en) * 2011-11-03 2015-06-24 Stc Biolog Inc METHOD FOR DETERMINING THE PHARMACOLOGICAL PROPERTIES OF RECOMBINANT PROTEINS
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
KR102202255B1 (ko) 2012-11-20 2021-01-13 옵코 바이오로직스 리미티드 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2016004242A1 (en) * 2014-07-01 2016-01-07 Stc Biologics, Inc. A method for development of recombinant proteins with fingerprint like similarity to the reference product
US10960058B2 (en) 2015-06-19 2021-03-30 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN118085104A (zh) 2016-07-11 2024-05-28 Opko生物科学有限公司 长效凝血因子及其制备方法
CN109415426B (zh) * 2016-07-12 2022-03-11 赫克萨尔股份公司 具有降低的唾液酸残基的乙酰化率的糖蛋白
JP7046173B2 (ja) * 2017-10-11 2022-04-01 エランコ・ユーエス・インコーポレイテッド ブタｇ－ｃｓｆ変異体とその使用
CN111514279B (zh) * 2020-06-16 2023-07-18 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
PT1012319E (pt) * 1997-03-27 2005-06-30 Univ British Columbia Vectores de expressao de insectos
CA2221819A1 (en) * 1997-03-27 1998-09-27 Thomas A. Gigliatti Insect expression vectors
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
JP2003520194A (ja) 1999-04-13 2003-07-02 ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド 末梢投与したエリスロポエチンによる興奮組織機能のモジュレート
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
SI1533380T1 (sl) * 1999-04-15 2010-03-31 Crucell Holland Bv Proizvajanje rekombinantnega proteina v človeški celici ki obsega vsaj en protein E adenovirusa
US20050164386A1 (en) 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FI109811B (fi) * 2000-09-26 2002-10-15 Medicel Oy Menetelmä GDP-L-fukoosin valmistamiseksi ja menetelmässä käytettäviä välineitä
DE10056136A1 (de) 2000-11-07 2002-05-16 Nemod New Modalities Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
EP2279755B1 (en) * 2001-10-10 2014-02-26 ratiopharm GmbH Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF)
AU2002335585B2 (en) 2001-10-29 2007-08-16 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
CA2560185C (en) 2004-03-17 2013-05-07 Crucell Holland B.V. Novel assay for the separation and quantification of hemagglutinin antigens
US7183371B2 (en) * 2004-11-01 2007-02-27 General Electric Company Method for making polycarbonate
US20080139608A1 (en) 2006-12-06 2008-06-12 Universiteit Leiden 2,6,8, Trisubstituted 1-deazapurines and their different uses

Also Published As

Publication number Publication date
WO2003038100A1 (en) 2003-05-08
EA012340B1 (ru) 2009-10-30
CA2756610C (en) 2015-08-25
US20050164917A1 (en) 2005-07-28
IL161674A (en) 2014-06-30
NO20042209L (no) 2004-07-28
US7785833B2 (en) 2010-08-31
ES2381104T3 (es) 2012-05-23
CN100347306C (zh) 2007-11-07
EP2292770A2 (en) 2011-03-09
US20080032922A1 (en) 2008-02-07
IL201673A (en) 2013-10-31
ATE542904T1 (de) 2012-02-15
CA2465007A1 (en) 2003-05-08
EP1440157A1 (en) 2004-07-28
JP4583029B2 (ja) 2010-11-17
EP2292770B1 (en) 2014-11-26
IL201674A (en) 2013-10-31
DK1440157T3 (da) 2012-05-07
CA2756610A1 (en) 2003-05-08
US7696157B2 (en) 2010-04-13
CA2465007C (en) 2012-01-17
EA008220B1 (ru) 2007-04-27
AU2002335585B2 (en) 2007-08-16
EP2292770A3 (en) 2012-12-19
EP1440157B1 (en) 2012-01-25
CN1578838A (zh) 2005-02-09
EA200602163A1 (ru) 2007-04-27
US7304031B2 (en) 2007-12-04
US20070117742A1 (en) 2007-05-24
BR0213402A (pt) 2004-10-13
JP2005507426A (ja) 2005-03-17

Similar Documents

Publication Publication Date Title
EA200602163A1 (ru) Способы и средства получения белков с заранее заданными посттрансляционными модификациями
DE59608743D1 (de) Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation
ATE119198T1 (de) Verfahren zur herstellung von proteinen mittels rekombinanter dna.
ATE289354T1 (de) Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
DE69434578D1 (de) Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren
DE3486179D1 (de) Verfahren zur herstellung vielkettige polypeptide oder proteine.
ATE500331T1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
DE69920747D1 (de) Methode zur herstellung von rekombinanten zellen
ATE140960T1 (de) Verfahren zur herstellung von zellen, die stabil integrierte fremde dns mit hoher kopiezahl enthalten, durch dieses verfahren hergestellte zellen und verwendung dieser zellen zur herstellung von durch diese fremde dns kodierten polypeptiden
DE60042122D1 (de) Fibroblasten wachstumsfaktor-ähnliche polypeptide
DE3851289D1 (de) Verfahren zur Züchtung rekombinanter Zellen.
KR910004803A (ko) 간의 실질 세포 성장 인자, 이를 코딩하는 유전자, 이 인자를 생산하는 방법, 및 이 인자를 생산하는 형질전환체
DE69939268D1 (de) Methoden zur aufreinigung von rekombinatem humanem erythropoietin aus zellkulturüberständen
DK0963377T3 (da) Interleukin-19
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
DE60122562D1 (de) Nukleinsäuren, die für stichodactylidae chromoproteine kodieren
ATE506370T1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
ATE223491T1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
ATE532793T1 (de) Verfahren zur herstellung von molekülen mit verminderter immunogenität
DE69425809D1 (de) Methoden zur Herstellung von Protein C
DE69922489D1 (de) Rekombinantes aktives humänes zona pellucida protein 3 (hzp3)
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung
DE69530261D1 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
WO2002059309A3 (en) Anthozoa derived chromoproteins, fluorescent mutants thereof and methods for using the same
ATE288476T1 (de) Herstellung von proteinen

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU